HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Remarkable improvement of the hip joint lesion in a patient with rheumatoid arthritis by the treatment with anti-TNF-α agents].

Abstract
22-year old woman who was previously diagnosed as having juvenile idiopathic arthritis (JIA) was treated with anti-TNF-α agents. Her disease activity was assessed as Stage IV and Class III by Steinbrocker's classification and resistant to steroids and methotrexate. Initially clinical findings responded well to infliximab (IFX), but polyarthritis recurred 15 months after the start of the treatment, and IFX was switched to etanercept (ETN) with good response. On the other hand, effects on the osteoarticular lesions were continuously observed through the period of the treatment with these two biologics. It was thought very rare that weight-bearing joint like the hip joint was restored as was seen in this case, while its mechanism is unknown. Because mechanism for inhibition of inflammation or joint destruction might be independent, we should investigate further the relationship between inflammation and joint destruction in the future.
AuthorsYasuaki Nagare, Koji Kinoshita, Fumiaki Nishisaka, Masakatsu Saito, Tohgo Nonaka, Masanori Funauchi
JournalNihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology (Nihon Rinsho Meneki Gakkai Kaishi) Vol. 33 Issue 5 Pg. 272-6 ( 2010) ISSN: 1349-7413 [Electronic] Japan
PMID21048388 (Publication Type: Case Reports, English Abstract, Journal Article)
Chemical References
  • Antirheumatic Agents
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • Etanercept
Topics
  • Antirheumatic Agents (therapeutic use)
  • Arthritis, Juvenile (drug therapy)
  • Etanercept
  • Female
  • Hip Joint
  • Humans
  • Immunoglobulin G (therapeutic use)
  • Receptors, Tumor Necrosis Factor (therapeutic use)
  • Tumor Necrosis Factor-alpha (antagonists & inhibitors)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: